A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

Condition:   Shigellosis Interventions:   Biological: Shigella 4V;   Biological: MenACWY;   Biological: Rabies;   Biological: Diphtheria, Tetanus and Pertussis (DTaP);   Biological: Placebo Sponsors:   LimmaTech Biologics AG;   Kenya Medical Research Institute;   KEMRI-Wellcome Trust Collaborative Research Program Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials